2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105919
    Naroparcil
    		Inhibitor
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration.
    Naroparcil
  • HY-151196
    FXIa-IN-10
    		Inhibitor
    FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good oral bioavailability.
    FXIa-IN-10
  • HY-145349
    FXIa-IN-6
    		Inhibitor
    FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM).
    FXIa-IN-6
  • HY-P4576
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa).
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
  • HY-10722
    DX-9065a
    		Inhibitor
    DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions.
    DX-9065a
  • HY-11090A
    DPC423
    		Inhibitor
    DPC423 is a highly potent, selective, and orally active factor Xa inhibitor with a Ki of 0.15 nM.
    DPC423
  • HY-P6023
    D-Leu-Pro-Arg-Rh110-D-Pro
    		Chemical
    D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro
  • HY-145354
    FXIa-IN-7
    		Inhibitor
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    FXIa-IN-7
  • HY-153836
    Anivamersen
    		Inhibitor
    Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen
  • HY-10269
    LY-517717
    		Inhibitor
    LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement.
    LY-517717
  • HY-153835A
    Pegnivacogin sodium
    		Inhibitor
    Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin sodium
  • HY-B0597R
    Fondaparinux (sodium) (Standard)
    		Inhibitor
    Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux (sodium) (Standard)
  • HY-P3009D
    Rat Factor Xa
    Rat Factor Xa is prepared by activating purified Rat Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Rat Factor Xa
  • HY-153817
    FXIa-IN-13
    		Inhibitor
    FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro.
    FXIa-IN-13
  • HY-10758
    FXa-IN-1
    		Inhibitor
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
    FXa-IN-1
  • HY-168712
    FXIa-IN-15
    		Inhibitor
    FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC1.5X of 0.55 μM.
    FXIa-IN-15
  • HY-10756
    BMS-740808
    		Inhibitor
    BMS-740808 is a potent, selective and orally active factor Xa inhibitor with a Ki of 30 pM. BMS-740808 shows >1000-fold for factor Xa than other proteases.
    BMS-740808
  • HY-P3009C
    Rabbit Factor Xa
    Rabbit Factor Xa is prepared by activating purified Rabbit Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Rabbit Factor Xa
  • HY-123356
    EMD-503982
    		Inhibitor
    EMD-503982 is an orally available FXa inhibitor.
    EMD-503982
  • HY-150682
    FXIa-IN-9
    		Inhibitor
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism.
    FXIa-IN-9
Cat. No. Product Name / Synonyms Application Reactivity